adult patients

Objective. To evaluate pharmacokinetics using therapeutic drug monitoring (TDM) data and develop a population pharmacokinetic/pharmacodynamic (PK/PD) model of linezolid for individualizing dosage regimens in critically ill adult patients in intensive care unit (ICU). Materials and Methods. A retrospective study of linezolid pharmacokinetics was conducted using TDM data (peak-trough strategy) and included data (n = 23) from patients treated in the ICU and receiving the standard linezolid dosing regimen of 600 mg intravenously twice daily.